



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 01 NOV 2004

WIPO PCT

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

03077971.4

**BEST AVAILABLE COPY**

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



Anmeldung Nr.:  
Application no.: 03077971.4  
Demande no:

Anmelde tag:  
Date of filing: 19.09.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

N.V. Nutricia  
Eerste Stationstraat 186  
2712 HM Zoetermeer  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Method and composition for preventing multiple organ dysfunction syndrome

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K9/00

Am Anmelde tag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignés lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI

METHOD AND COMPOSITION FOR PREVENTING MULTIPLE ORGAN  
DYSFUNCTION SYNDROME

## 5 TECHNICAL FIELD OF THE INVENTION

One aspect of the present invention relates to a method of preventing multiple organ dysfunction syndrome following trauma. The present method comprises enteral administration of a liquid nutritional composition shortly before and/or after the occurrence of a trauma.

Another aspect of the invention concerns a liquid nutritional composition for use in the aforementioned method.

## 15 BACKGROUND OF THE INVENTION

With the advent of sophisticated monitoring systems and more effective single-organ support, the chances of patients being resuscitated from acute trauma are continuously increasing. However, following the "survival" of the initial phase of critical illness, these patients frequently progress into the clinical syndrome of Multiple Organ Dysfunction. MOD is characterized by a progressive deterioration and subsequent failure of the bodies physiological system<sup>1</sup>. Because no effective treatments have been developed so far, MOD is associated with high mortality rates.

Multiple organ dysfunction is no longer viewed as a series of isolated failures. On autopsy, the involved organs display similar patterns of tissue damage although they are often remote from the initial injury site or septic source. This complex syndrome, once thought to be solely related to cardiovascular dysfunction and/or isolated organ failure, is now recognized as a systemic disturbance mediated by a sustained inflammatory response to injury, regardless of the initiating factor(s). The multiple organ dysfunction syndrome attests to the complex interaction between organ systems in both their functioning and pathological states.

Several mechanisms have been postulated to be involved in post-ischemia induction of MOD. The gut-liver-lung axis has been associated to play a dominant role in the incidence and severity of this single and multiple organ dysfunction (S)MOD <sup>2-7</sup>. More specifically, the intestine is often referred to as the driving force of multiple organ dysfunction <sup>8-11</sup>. The post-ischemic increase in reactive oxygen species can directly or indirectly (by macrophages and lymphocytes) activate neutrophils that subsequently can infiltrate at the site of inflammation causing tissue injury. These neutrophils have recently also been reported to increase paracellular transport in ileum. This damage of the intestinal barrier has often been mentioned to result in increased trans-epithelial bacterial transport and their endotoxins resulting in an inflammatory challenge of the patient, which has been reported to be involved in the incidence of MOD.

Recently, oxidative stress and neutrophil activation have been suggested as the two keystones of ischemia reperfusion injury <sup>12</sup>. It is generally accepted that upon reperfusion (post-ischemia) a burst of ROS are released by several mechanisms, which may exceed the body's anti-oxidant capacity causing oxidative stress <sup>13-18</sup>. Importantly, these ROS activate the inflammatory transcription factor NF- $\kappa$ B. Although an inflammatory response may be necessary, control of the inflammatory response is greatly lost after ischemia and therefore the pro-inflammatory cytokines TNF $\alpha$  and IL-6 may be aggravated beyond their need. The importance of these ROS in NF- $\kappa$ B induction is for instance demonstrated by addition of N-acetylcysteine, which upregulates glutathione levels in blood plasma, resulting in a decreased NF $\kappa$ B response and subsequently lowered TNF $\alpha$  <sup>12</sup>.

Preoperative fasting has been reported to alter the morphological and metabolic responses to stress <sup>19-21</sup> e.g. translocation of bacterial and their endotoxins has been reported to increase <sup>22-24</sup>. This increased translocation can be due to either decreased intestinal barrier function, a decreased hepatic function, especially the Kupffer cells P3 of the hepatic reticuloendothelial system (RES) or both. Moreover, dysfunction of the reticuloendothelial system (RES) system due to intestinal ischemia has been reported, especially in fasted animals <sup>25-28</sup>.

EP-A 0 564 511 discloses a beverage for preoperative intake consisting of an aqueous solution which is hypotonic (250-295 mOsm/kg) and contains 8-20 g of carbohydrates per 100 ml. The beverage may be used for suppressing the negative

influence of a surgical operation on the post-operative carbohydrate metabolism of the patient and for improving the defence capacity of the patient upon bleeding in connection with or after surgery.

EP-A 0 875 155 describes a liquid nutritional composition for peri-operative use which contains per 400 ml, 5-130 g soluble carbohydrates and 1-30 g glutamine or a glutamine precursor calculated as glutamine. The liquid composition is to be administered shortly before or after surgery to maintain anabolic metabolism without causing problems of anaesthesia and emptying of the stomach.

10

## SUMMARY OF THE INVENTION

Before scheduled surgery, patients are usually subjected to fasting for at least 8 hours, up to 24 hours, for reasons of safety with regard to anaesthesia and for preventing regurgitation of the stomach content and aspiration. Also, following surgery or severe trauma, patients often will not consume any nutrients for 8 hours or more.

The inventors have unexpectedly discovered that there is a correlation between the incidence of MOD following trauma and reduced intake of digestible carbohydrates as a result of fasting during the period shortly before and/or after the occurrence of the trauma. Furthermore, the inventors have established that the risk of MOD may be reduced significantly by enterally administering shortly before or after the occurrence of the trauma, a substantial amount of digestible water soluble carbohydrates in the form of an aqueous liquid composition containing said digestible water soluble carbohydrates.

The experimental data suggest that animals that are peri-operatively fed with a carbohydrate solution, as compared to fasted animals, develop significantly less intestinal permeability and also suffer from much less translocation of bacteria to liver, kidney and mesenteric lymphnodes. These data are further supported by biochemical characterizations of oxidative stress per organ and energy status of the liver.

Although the inventors do not wish to be bound by theory it is believed that the mechanism behind the protective effect of peri-operative administration of digestible carbohydrates on the incidence of MOD is somehow associated with the effect of said

administration on both the intestine and the liver. The results indicate that the present method supports the maintenance of the gut barrier function after trauma.

Having established the relation between essential liver functioning and MOD, the inventors have additionally discovered that the prophylactic effect of the present liquid composition on MOD is further enhanced by incorporating into said composition an effective amount of one or more components capable of increasing liver guanosine-5'-triphosphate (GTP).

## 10 DETAILED DESCRIPTION OF THE INVENTION

Accordingly, one aspect of the invention is concerned with a method of preventing multiple organ dysfunction syndrome in a mammal suffering from trauma, said method comprising enterally administering to said mammal, within 24 hours of the occurrence of the trauma, at least 20 g of the digestible water soluble carbohydrates in the form of an aqueous liquid composition containing at least 10 g/l, preferably at least 20 g/l of said digestible water soluble carbohydrates.

The terminology "digestible carbohydrates" as used herein refers to carbohydrates that can either be absorbed as such by the gastrointestinal tract or that can be degraded by the gastrointestinal tract to absorbable components, provided said degradation does not involve fermentative degradation by the intestinal microflora.

The terminology "enterally administering" encompasses oral administration (including oral gavage administration) as well as rectal administration, oral administration being most preferred.

Unless indicated otherwise, the dosages mentioned in this application refer to the amounts delivered during a single serving or single administration event. If the present composition is ingested from a glass or a container, the amount delivered during a single serving or single administration will typically be equal to the content of said glass or container.

Examples of trauma that can lead to MOD that can be treated prophylactically with the present method include surgery and major injuries such as burns, lesions and haemorrhage. The present method is particularly suitable for preventing MOD resulting from surgery, particularly prescheduled surgery. In case of, for instance, prescheduled

surgery it is possible to administer the present liquid composition prior to the occurrence of the trauma. Administration of the liquid composition prior to the occurrence of the trauma offers the important advantages that the composition can be administered simply by asking the patient to drink it and that the effect will be manifest when the actual trauma occurs.

The digestible carbohydrates employed in accordance with the invention may suitably include monosaccharides, disaccharides and polysaccharides. In a particularly preferred embodiment of the present invention the digestible water soluble carbohydrates are largely glucose based. In accordance with this embodiment said digestible water soluble carbohydrates optionally contain saccharides other than glucose in amounts of up to 6%, calculated on the molecular weight of the digestible carbohydrate. Examples of other saccharides that may occur in the digestible glucose based carbohydrates include D-fructose, D-arabinose, D-rhamnose, D-ribose and D-galactose, though preferably these saccharides are not located at the terminal side of the present carbohydrates. The glucose units of oligo - and polysaccharides are preferably predominantly connected via alpha 1-4 or alpha 1-6 bonds in order to be digestable. The digestible carbohydrates of the invention encompass both linear and branched oligo- and polysaccharides. The number of saccharide units is indicated via a number n. Oligosaccharides have a number of n between 3 and 10; polysaccharides between 11 and 1000 and preferably between 11 and 60.

Preferably, the present liquid composition contains between 30 and 200 g/l of digestible polysaccharides since, in comparison to monosaccharides and disaccharides, polysaccharides are absorbed more slowly. In another preferred embodiment, the composition contains a combination of polysaccharides and mono- and/or disaccharides. More preferably, the digestible carbohydrates comprise between 60-99 wt.% digestible oligo- and/or polysaccharide and between 1-40 wt.% digestible mono- and/or disaccharides. A suitable example of a digestible water soluble oligosaccharide is glucose syrup. Suitable examples of the digestible water soluble polysaccharides include dextrans, maltodextrins, starches, dextran and combinations thereof. Most preferably the water soluble polysaccharide contains at least 50 wt.%, more preferably at least 80 wt.% of polysaccharides selected from the group consisting of dextrin, maltodextrin and combinations thereof, dextrin being most preferred. In a particularly preferred embodiment the digestible carbohydrates include at least 1 wt.%

monosaccharide, particularly at least 1 wt.% fructose. Typically, the digestible carbohydrates will contain not more than 20 wt.% fructose in monosaccharide form.

In a particularly preferred embodiment of the invention, the method comprises enterally administering, within 24 hours of the occurrence of the trauma, at least 50 g, 5 more preferably at least 70 g of the digestible water soluble carbohydrates in the form of the aqueous liquid composition. The liquid composition may be administered as a single bolus or, alternatively, it may be administered in two or more doses during the 24 hour period. Preferably, the liquid composition is administered in at least 2 separate doses during the 24 hours period, the administration events preferably being at least 1 10 hour apart. A particularly suitable protocol comprises administering a sufficient amount of the present liquid composition during the period ranging from 24-8 hours prior to the trauma to deliver at least 40 g of digestible carbohydrates and to deliver at least 20 g of digestible carbohydrates during the period of 8-1 hour prior the trauma.

The inventors have discovered an inverse relation between liver guanosine-5'-triphosphate (GTP) and the incidence of MOD. Liver GTP levels may be increased effectively in accordance with the present invention by administering guanosine, folic acid and/or ribose or precursors thereof. Thus, in a preferred embodiment, the present method comprises administering, within 24 hours of the occurrence of the trauma, a liver GTP increasing component selected from the group consisting of:

20 2-2000 mg, preferably 2-400 mg, more preferably 5-40 mg guanosine equivalents; 0.1-10 mg, preferably 0.2-5 mg folic acid equivalents; 0.5-40 g, preferably 3-10 g ribose equivalents, more preferably 2-10 g D-ribose equivalents; and combinations thereof.

25 The term "guanosine equivalents" as used in here, encompasses guanosine as well as salts of guanosine and precursors of guanosine, notably precursors that can liberate guanosine or a guanosine salt by *in vivo* conversion, e.g. hydrolysis, of the precursor molecule. The term "folic acid equivalents" encompasses folic acid as well as salts of folic acid and precursors of folic acid or folic acid salts, notably precursors that 30 can liberate folic acid, a folic acid salt or a metabolically active form of folic acid by *in vivo* conversion, e.g. hydrolysis, of the precursor molecule. Examples of suitable precursors include tetrahydrofolic (tetrahydropteroyl) polyglutamate, tetrahydrofolic glutamate, and 5-methyl and/or 10-methyl substituted analogues thereof. The folic acid

equivalents according to the present invention may also comprise a pteroyl group in the dihydro form, be it that it is preferred to use the tetrahydro form..

The term "ribose equivalents" is defined in accordance with the definitions provided above for guanine equivalents and folic acid equivalents. Ribose equivalents 5 may be administered in the form of synthetic or natural ribose or, for instance, as a precursor in the form of a nucleobase adduct, e.g. as a ribose guanosine adduct.

The inclusion of folic acid in the indicated concentration range provides support for the biosynthesis of GTP. Another advantage of the use of folic acid in accordance with the present invention is the favourable impact on ADMA plasma concentrations 10 (see below) <sup>29</sup>. A combination of folic acid and ribose is particularly effective in maintaining/restoring liver GTP levels. Hence, in a particularly preferred embodiment the present method employs a combination of folic acid and ribose.

In a particularly preferred embodiment, the present method comprises administering, within 24 hours of the occurrence of the trauma, 2-100 mg guanosine 15 equivalents, more preferably 5-40 mg guanosine equivalents. Guanosine is a precursor of GTP. Unexpectedly, the inventors have discovered that other potential precursors of GTP, e.g. guanine and guanosine monophosphate (GMP) are far less suitable.

Increased plasma levels of asymmetric dimethylarginine (ADMA) are deemed to constitute an additional risk factor for MOD. It was found that the inclusion of an 20 effective amount of peptides with ACE inhibiting activity in the present liquid composition will help to prevent that plasma concentrations of ADMA reach undesirably high levels. Thus, in a very preferred embodiment of the invention, the present method comprises administering, within 24 hours of the occurrence of the trauma, 0.05-100 mmoles, preferably 0.1-50 mmoles of peptides with Angiotensin 25 Converting Enzyme (ACE) inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M. The IC-50 concentration is a measure of the potency of a substance or composition to inhibit ACE activity and may be determined as described below under "Methods".

Although the inventors do not wish to be bound by theory, it is believed that 30 ACE inhibitors may be able to increase the bio-availability of NO to endothelial cells, thereby improving endothelial function. ADMA is cleared by excretion into urine and by metabolism by dimethylarginine dimethylaminohydrolase, which is abundantly expressed in liver and kidney, and also in endothelial cells. It is hypothesised that the

clearance function of both liver and kidney is mediated by the endothelial cells in these highly vascularised organs. Thus, the vitality of the endothelial cells would be vital for the clearance of ADMA. This hypothesis is further supported by the observation that ADMA levels are usually increased in subjects with vascular diseases or with risk factors for vascular diseases, such as hypercholesterolemia and hypertension. In all these conditions endothelial function is compromised, whereas liver and kidney function are often unaffected.

In yet another advantageous embodiment of the invention the present method comprises co-administering, within 24 hours of the occurrence of the trauma, flavonoids in an amount of 0.5-200 mg, preferably of 1-100 mg and most preferably of 5-50 mg. Flavonoids, such as luteolin, quercetin and apigenin, were found to be good xanthine oxidase inhibitors and to inhibit oxidative stress, as demonstrated by their effect on plasma concentrations of malon dialdehyde. In addition, flavonoids were also found to assist in the maintenance and restoration of liver GTP level. In a particularly preferred embodiment, the present composition contains flavonoids selected from the group consisting of luteolin, quercetin, apigenin and combinations thereof, preferably in a concentration of at least 2 mg/l, more preferably of at least 5 mg/l, most preferably of at least 10 mg/l.

Another aspect of the invention relates to an aqueous liquid composition for use in the present in the present method. More particularly, this aspect concerns an aqueous liquid composition suitable for enteral administration containing: 20-200 g/l digestible dissolved carbohydrates; 5-5000 mg/l guanosine equivalents; and 45 to 97.95 wt.% water.

Preferably, the present liquid composition contains 5 mg/l guanosine equivalents, more preferably at least 10 mg/l guanosine equivalents. Generally, the concentration of guanosine equivalents in the composition will not exceed 2000 mg/l, preferably it will not exceed 1000 mg/l, more preferably it will not exceed 500 mg/l.

In a particularly preferred embodiment of the invention, the liquid composition contains between 0.01 and 10 mM of peptides with Angiotensin Converting Enzyme (ACE) inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M.

Yet another aspect of the invention relates to an aqueous liquid composition suitable for enteral administration containing:

- 20-200 g/l digestible dissolved carbohydrates;
- 0.01 to 10 mM of peptides with ACE inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M.; and
- 45 to 97.95 wt.% water.

Preferably, the present composition contains a peptide with ACE inhibiting activity or a blend of such peptides in a concentration that is not below 10%, preferably not below 50% of the IC-50 concentration of said peptide or said blend of peptides.

ACE inhibiting peptides may suitably be incorporated in the present composition in the form of protein hydrolysates, particularly milk protein hydrolysates.

In another preferred embodiment, the liquid composition of the invention contains between 0.2 and 400 mg/l folic acid equivalents. More preferably, said composition contains between 0.5 and 100 mg/l folic acid equivalents. In a particularly preferred embodiment the liquid composition additionally contains 1-100 g/l, preferably 3-50 g/l ribose equivalents.

In yet another advantageous embodiment of the invention the aqueous liquid composition contains flavonoids in a concentration of 2-2000 mg/l. Preferably, flavonoids are contained in the present composition in a concentration of at least 5 mg/l, more preferably of at least 10 mg/l. Usually, the flavonoid concentration will not exceed 1000 mg/l, preferably it does not exceed 500 mg/l. Flavonoids, such as luteolin, quercetin and apigenin, were found to be good xanthine oxidase inhibitors and to inhibit oxidative stress, as demonstrated by their effect on plasma concentrations of malon dialdehyde. In addition, flavonoids were also found to assist in the maintenance and restoration of liver GTP level. In a particularly preferred embodiment, the present composition contains flavonoids selected from the group consisting of luteolin, quercetin, apigenin and combinations thereof in a concentration of at least 2 mg/l, preferably of at least 5 mg/l.

For patients who find it difficult to swallow or who experience nausea etc., it is important that the digestible carbohydrates can be delivered in concentrated liquid form. Consequently, it is preferred to include the digestible water soluble carbohydrates in a concentration of at least 50 g/l, more preferably of at least 70 g/l and most preferably at least 80 g/l.

In order to minimise the risk of regurgitation and also to minimise the residence time in the stomach, it is preferred that the liquid composition contains less than 30 g/l lipids, more preferably less than 20 g/l lipids and most preferably less than 10 g/l lipids. For similar reasons, also the protein level of the present composition is preferably relatively low, especially below 40 g/l. Another way to reduce the risk of regurgitation is to reduce the volume size of the serving (e.g. to less than 100 ml), or to apply a tube in the duodenum.

The present liquid composition may, for instance, take the form of a solution, a suspension or an emulsion. It is preferred to employ a liquid composition in the form of a solution that contains essentially no undissolved components, e.g. as demonstrated by the fact the liquid composition is clear and transparent.

Yet another aspect of the present invention relates to a composition that can be reconstituted with water to the present aqueous liquid composition. Typically, the reconstitutable composition can take the form of a liquid concentrate, a paste, a powder, granules, tablets etc. Preferably, the reconstitutable composition is a dry product, particularly a dry product with a moisture content of less than 10 wt.%, preferably of less than 7 wt.%.

## 20 REFERENCES

1. Thomson AB, Keelan M, Thiesen A, et al. Small bowel review: diseases of the small intestine. *Dig Dis Sci* 2001; 46(12):2555-66.
2. Baue AE. Nutrition and metabolism in sepsis and multisystem organ failure. *Surg Clin North Am* 1991; 71(3):549-65.
3. Pugin J, Chevrolet JC. [ The intestine-liver-lung axis in septic syndrome]. *Schweiz Med Wochenschr* 1991; 121(42):1538-44.
4. Matuschak GM. Liver-lung interactions in critical illness. *New Horiz* 1994; 2(4):488-504.
5. Tadros T, Traber DL, Herndon DN. Hepatic blood flow and oxygen consumption after burn and sepsis. *J Trauma* 2000; 49(1):101-8.
6. Towfigh S, Heisler T, Rigberg DA, et al. Intestinal ischemia and the gut-liver axis: an in vitro model. *J Surg Res* 2000; 88(2):160-4.
7. Zeuzem S. Gut-liver axis. *Int J Colorectal Dis* 2000; 15(2):59-82.
8. Yao Y, Yu Y, Wu Y, et al. The role of gut as a cytokine-generating organ in remote organ dysfunction after intestinal ischemia and reperfusion. *Chin Med J (Engl)* 1998; 111(6):514-8.
9. Nieuwenhuijzen GA, Deitch EA, Goris RJ. The relationship between gut-derived bacteria and the development of the multiple organ dysfunction syndrome. *J Anat* 1996; 189(Pt 3):537-48.
10. Nieuwenhuijzen GA, Deitch EA, Goris RJ. Infection, the gut and the development of the multiple organ dysfunction syndrome. *Eur J Surg* 1996; 162(4):259-73.
11. Baue AE. The role of the gut in the development of multiple organ dysfunction in cardiothoracic patients. *Ann Thorac Surg* 1993; 55(4):822-9.
12. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation—the two keystones of ischemia/reperfusion injury. *Int J Cardiol* 2002; 86(1):41-59.

13. Akcakaya A, Alimoglu O, Sahin M, Abbasoglu SD. Ischemia-reperfusion injury following superior mesenteric artery occlusion and strangulation obstruction. *J Surg Res* 2002; 108(1):39-43.

5 14. Canas PE. The role of xanthine oxidase and the effects of antioxidants in ischemia reperfusion cell injury. *Acta Physiol Pharmacol Ther Latinoam* 1999; 49(1):13-20.

15. Moore RM, Muir WW, Granger DN. Mechanisms of gastrointestinal ischemia-reperfusion injury and potential therapeutic interventions: a review and its implications in the horse. *J Vet Intern Med* 1995; 9(3):115-32.

10 16. Lai HS, Chen WJ, Chiang LY. Free radical scavenging activity of fullerol on the ischemia-reperfusion intestine in dogs. *World J Surg* 2000; 24(4):450-4.

17. Nakamura M, Ozaki M, Fuchinoue S, et al. Ascorbic acid prevents ischemia-reperfusion injury in the rat small intestine. *Transpl Int* 1997; 10(2):89-95.

18. Gunel E, Caglayan F, Caglayan O, et al. Treatment of intestinal reperfusion injury using antioxidative agents. *J Pediatr Surg* 1998; 33(10):1536-9.

15 19. Grynberg A, Demaison L. Fatty acid oxidation in the heart. *J Cardiovasc Pharmacol* 1996; 28(Suppl 1):S11-7.

20. Longarela A, Olarra J, Suarez L, Garcia de Lorenzo A. [Metabolic response to stress, can we control it?]. *Nutr Hosp* 2000; 15(6):275-9.

21. Ma SW, Foster DO. Starvation-induced changes in metabolic rate, blood flow, and regional energy expenditure in rats. *Can J Physiol Pharmacol* 1986; 64(9):1252-8.

20 22. Bark T, Katouli M, Svenberg T, Ljungqvist O. Food deprivation increases bacterial translocation after non-lethal haemorrhage in rats. *Eur J Surg* 1995; 161(2):67-71.

23. Salman FT, Buyruk MN, Gurler N, Celik A. The effect of surgical trauma on the bacterial translocation from the gut. *J Pediatr Surg* 1992; 27(7):802-4.

25 24. Nettelbladt CG, Katouli M, Volpe A, et al. Starvation increases the number of coliform bacteria in the caecum and induces bacterial adherence to caecal epithelium in rats. *Eur J Surg* 1997; 163(2):135-42.

25 25. Loegering DJ, Feintuch JJ. Depression of the reticuloendothelial system following graded isoproterenol-induced myocardial injury. *Circ Shock* 1979; 6(4):385-9.

30 26. Haglind B, Wang D, Klein AS. Hepatic reticuloendothelial system dysfunction after intestinal ischemia-reperfusion. *Shock* 1996; 5(1):72-5.

27. Klein AS, Zhadkevich M, Wang D, et al. Discriminant quantitation of posttransplant hepatic reticuloendothelial function. The impact of ischemic preservation. *Transplantation* 1996; 61(8):1156-61.

35 28. Brengman ML, Wang D, Wilkins KB, et al. Hepatic killing but not clearance of systemically circulating bacteria is dependent upon peripheral leukocytes via Mac-1 (CD11b/CD18). *Shock* 2003; 19(3):263-7.

29. Holven KB, Haugstad TA, Holm T et al. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. *Br J Nutr* 2003 89(3); 359-63

40 .

## METHODS

45

### *Determination of the IC-50 concentration*

The IC-50 concentration as referred to in this application is the concentration at which a substance reduces the activity of angiotensin converting enzyme (ACE) by 50%, using the testing conditions as described below.

50

ACE is capable of cleaving a substrate, FAPGG (N-[3-(2-furyl) acryloyl]-L-phenylalanylglycylglycine), into FAP and GG. The intact substrate is

spectrophotometrically detectable at a wavelength of 340 nm. The cleavage products are not detectable at said wavelength. The absorbance of an aqueous solution of the substrate to which ACE is added will decrease over time as result of the enzymatic cleavage of the substrate. In order to assess the ACE inhibiting properties of substances, these substances are introduced into the ACE-substrate mixture at different concentrations. The absorbance at 340 nm is followed for 20 minutes and the rate at which the absorption decreases is calculated from this data.

5 The method employs positive and negative controls for calibration.

Negative control: ACE and FAPGG (without test substance)

10 Positive control: ACE/FAPGG and pharmacological ACE inhibitor (e.g. Captotril, 25 nM)

Materials:

15 96 wells plate

Microplate reader (340 nm filter; kinetic protocol)

Angiotensin Converting Enzyme, 0.16 mU/ $\mu$ l, ex Sigma® (A-6778)

FAPGG, 2 mg/ml (5mM) ex Sigma® (F-7131)

ACE-buffer : 17.6 mg/ml (300 mM) NaCl, 12 mg/ml (50 nM) Hepes, pH 7.5

20 Method:

- Adjust the incubator of the microplate reader to 37°C
- Dissolve and dilute the test components in the ACE buffer
- Pipet 60  $\mu$ l per well of the samples (including positive and negative controls) in the 96-wells plate
- 25 ▪ Add 30  $\mu$ l per well of FAPGG (2 mg/ml in ACE buffer)
- Incubate the plate at 37°C for 5 minutes
- Add 10  $\mu$ l per well of ACE (0.16 mU/  $\mu$ l)
- Measure the absorbance at 340 nm for 20 minutes (kinetic protocol, 80 readings, one reading every 15 seconds)

30

## EXAMPLES

Example 1

An aqueous liquid composition to be administered in a serving of 200 ml, comprising

5 per 100 ml:

Glucose	1 g
Maltodextrin DE 5	10 g
Guanosine	5 mg

The liquid is to be administered in two servings within 24 hours of the occurrence of a

10 trauma.

Example 2

An aqueous liquid composition to be administered in a serving of 200 ml, comprising

per 100 ml:

15	Glucose syrup DE 12	11.5 g
	Glucose	2 g
	Folic acid	100 $\mu$ g
	Guanosine	2 mg

The liquid is to be administered in three servings within 24 hours of the occurrence of a

20 trauma.

Example 3

An aqueous liquid composition to be administered in a serving of 200 ml, comprising

per 100 ml:

25	Dextrin	11.5 g
	Glucose	2 g
	Folic acid	100 $\mu$ g
	$\alpha_{s1}$ -Casein hydrolysate <sup>#</sup>	7 g

# Ex DMV International; containing 6% C12 peptide

30 The liquid is to be administered in four servings within 24 hours of the occurrence of a trauma.

Example 4

An aqueous liquid composition to be administered in a serving of 125 ml, comprising per 100 ml:

	Glucose syrup DE 19	11.5 g
5	Glucose	2 g
	Folic acid	200 $\mu$ g
	Casein hydrolysate <sup>§</sup>	1.75 g

<sup>§</sup> containing 0.05 g (76  $\mu$ mole) ACE inhibiting peptide with IC-50 of 6  $\mu$ M

The liquid is to be administered in four servings within 24 hours of the occurrence of a  
10 trauma.

Example 5

An aqueous liquid composition to be administered in a serving of 200 ml, comprising per 100 ml:

	Maltose	1 g
	Glucose syrup DE 29	10 g
	Folic acid	200 $\mu$ g
	GTP	5 mg
	Ribose	1 g

20 Soy protein hydrolysate <sup>@</sup> 2 g  
<sup>@</sup> containing at least 0.1 g ACE inhibiting peptide with IC-50 of less than 200  $\mu$ M

The liquid is to be administered in two servings within 24 hours of the occurrence of a  
trauma.

25

Example 6

An aqueous liquid composition to be administered in a serving of 500 ml, comprising per 100 ml:

	Maltose	1 g
	Glucose syrup DE 32	10 g
	Folic acid	50 $\mu$ g
	GTP	1 mg
	Ribose	0.5 g

$\alpha_{s1}$ -Casein protein hydrolysate \* 2 g

\* ex DMV International; containing 8% C12 peptide

The liquid is to be administered in two servings within 24 hours of the occurrence of a trauma by means of tube feeding.

5

Example 7

A powder formulation to be reconstituted to a single serving with 200 ml water:

Dextrin 23 g

Glucose 4 g

10 Folic acid 200  $\mu$ g

Casein hydrolysate # 1.74 g

# containing 0.05 g ACE inhibiting peptide with IC-50 of 5  $\mu$ M

The reconstituted liquid is to be administered four times within 24 hours of the occurrence of a trauma.

15

Example 8

Rat studies were carried out to elucidate whether pre-operative supplementation with carbohydrates improves post-operative organ function and decreases multiple organ dysfunction-associated risk factors.

20

*Methods:*


One group of male wistar rats were fasted for 16 hours (water *ad libitum*), prior to clamping the SMA. The intervention group received 113 g of dextrin and 12.7 g fructose per litre, plus an isotonic mix of salts and citric acid in drinking water, starting 5 days before the operation and continued until the day of operation. *Ad libitum* water served as control. The animals were sacrificed by exsanguination; intestinal permeability and translocation of bacteria were measured immediately, plasma and different organ samples were frozen in liquid nitrogen, for organ function parameters measurements. Sham-fasted animals served as controls.

25

30

5 **Results - Intestine**


Ischemia reperfusion in the fasted animals resulted in a significant increased intestinal permeability (Fig 1). Preoperative ad libitum administration of a carbohydrate drink showed to preserve a significantly ( $P<0.05$ ) better intestinal barrier function when compared to overnight fasted ischemic rats (Fig 1).




[Fig 1. Intestinal permeability]

10 **Results - Bacterial translocation**


15 Fasted operated rats showed an increased bacterial translocation to the liver, kidney and mesenteric lymph nodes (Fig 2A-C.) when compared to sham fasted rats or sham fed rats. Preoperative supplementation of the carbohydrate drink significantly decreased bacterial translocation to the liver, kidney and mesenteric lymph nodes (Fig 3A-C.) as compared to IR fasted animals. Furthermore, a trend ( $P=0.07$ ) to decreased bacterial translocation was seen in the spleen of preoperative fed animals (Fig 2D.).




2A



5 2B



2C



2D

[Fig 2 translocation of bacteria]

5


**Results - Lung**

The lung, showed increased neutrophil infiltration as indicated by myeloperoxidase activity (Fig.3A.) in the IR fasted group when compared with the sham-fasted group. The group, pre-operatively supplemented with the carbohydrate mixture showed a significant ( $P<0.02$ ) decrease when compared to the IR fasted rats (Fig.2A.). Moreover, the IR fasted group showed significantly ( $P=0.014$ ) decreased GSH concentration compared to the pre-operative supplemented group. In contrast, the GSH concentration of the IR supplemented group was almost retained at the level of the sham fasted animals (Fig. 3B).


Oxidative stress, indicated as MDA concentration, showed a trend ( $P<0.1$ ) to decrease when compared to IR fasted animals.

10

15



3A




5 3B

[Fig 3 Lung inflammation and oxidative capacity]

#### Results - Systemic parameter

10 Rats that were allowed *ad libitum* pre-operative access to the carbohydrate drink showed a significant ( $P=0.028$ ) decrease in urea concentration when compared to IR fasted rats (Fig 4).




[Fig 4 plasma urea]


*Results - Plasma ADMA and IL-6 concentration*

Asymmetrical dimethylarginine (ADMA) concentration, recently suggested to be a risk factor for organ dysfunction, was significantly increased in the IR fasted rats ( $P<0.02$ ) as compared to sham-fasted (Fig. 5A.). Importantly, the pre-operative supplemented group showed significantly ( $P<0.01$ ) decreased ADMA concentration and were shown to be deprived from an increase in ADMA when compared to IR fasted and sham-fasted animals respectively (Fig. 5A.)

Another parameter that has concentration-dependently been linked to the incidence and severity of single and multiple organ dysfunction ((S)MOD) is IL-6, a pro-inflammatory cytokine. The IL-6 concentration showed a significant ( $P=0.02$ ) decrease in the group pre-operatively supplemented with the carbohydrate mixture as compared to the IR fasted rats (Fig 5B).



5A



5 B

[Fig 5 ADMA and IL-6 concentrations]

### Conclusions

In conclusion, pre-operative administration of carbohydrates decreased MOD. This decrease was shown by improved intestinal barrier function and lowered bacterial translocation. Furthermore, lung inflammation pulmonary oxidative stress and plasma urea were decreased. These improvements in organ function parameters in the carbohydrate-fed rats were paralleled by a simultaneous decrease in ADMA and IL-6

10

concentration. The beneficial effects of preoperative carbohydrate supplementation on decreasing MOD and MOD associated factors suggest an important role for preoperative nutrition to improve post-operative recovery.

## CLAIMS

(72)

1. Use of digestible water soluble carbohydrates in the manufacture of an aqueous liquid composition for use in a method of preventing multiple organ dysfunction in a 5 mammal suffering from trauma, said method comprising enterally administering to said mammal, within 24 hours of the occurrence of the trauma, at least 20 g of the digestible water soluble carbohydrates in the form of an aqueous liquid composition containing at least 10 g/l of said digestible water soluble carbohydrates.
- 10 2. Use according to claim 1, wherein the trauma is surgery, preferably prescheduled surgery.
- 15 3. Use according to claim 1 or 2, wherein the liquid composition is administered prior to the occurrence of the trauma.
4. Use according to any one of the preceding claims, wherein the liquid composition contains between 30 and 200 g/l of digestible polysaccharides.
- 20 5. Use according to any one of the preceding claims, wherein the digestible water soluble carbohydrates are selected from the group consisting of dextrins, maltodextrins, starches, dextran and combinations thereof.
- 25 6. Use according to any one of the preceding claims, wherein the method comprises enterally administering, within 24 hours of the occurrence of the trauma, at least 50 g of the digestible water soluble carbohydrates in the form of the aqueous liquid composition.
- 30 7. Use according to any one of the preceding claims, wherein the method comprises administering, within 24 hours of the occurrence of the trauma, a liver guanosine-5'-triphosphate (GTP) increasing component selected from the group consisting of: 2-2000 mg guanosine equivalents; 0.1-10 g folic acid equivalents; 0.5-40 g ribose equivalents; and combinations thereof.

8. Use according to claim 7, wherein the method comprises administering, within 24 hours of the occurrence of the trauma, 2-2000 mg guanosine equivalents.

9. Use according to any one of the preceding claims, wherein the method 5 comprises administering, within 24 hours of the occurrence of the trauma, 0.05-100 mmole of peptides with Angiotensin Converting Enzyme (ACE) inhibiting activity, said peptides exhibiting an IC-50 concentration as defined in the specification of less than 1000  $\mu$ M.

10 10. An aqueous liquid composition suitable for enteral administration containing:  
■ 20-200 g/l digestible dissolved carbohydrates;  
■ 5-5000 mg/l guanosine equivalents; and  
■ 45 to 97.95 wt.% water.

15 11. Liquid composition according to claim 10, wherein the composition contains between 0.01 and 10 mM of peptides with Angiotensin Converting Enzyme (ACE) inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M.

20 12. An aqueous liquid composition suitable for enteral administration containing:  
■ 20-200 g/l digestible dissolved carbohydrates;  
■ 0.01 to 10 mM of peptides with ACE inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M; and  
■ 45 to 97.95 wt.% water.

25 13. Liquid composition according to any one of claims 10-12, wherein the composition contains between 0.2 and 400 mg/l folic acid equivalents.

30 14. Liquid composition according to any one of claims 10-13, wherein the composition contains flavonoids in a concentration within the range of 2-2000 mg/l.

15. Liquid composition according to any one of claims 10-14, wherein the liquid composition is a clear aqueous solution.

16. A composition that can be reconstituted with water to a liquid composition according to any one of claims 10-15.

19 09. 2003

## ABSTRACT

(72)

One aspect of the present invention relates to a method of preventing multiple organ dysfunction syndrome in a mammal suffering from trauma, said method comprising enterally administering to said mammal, within 24 hours of the occurrence of the trauma, at least 20 g of the digestible water soluble carbohydrates in the form of an aqueous liquid composition containing at least 10 g/l, preferably at least 20 g/l of said digestible water soluble carbohydrates.

Another aspect of the invention relates to an aqueous liquid composition containing: 20-200 g/l digestible dissolved carbohydrates; 5-5000 mg/l guanosine equivalents; and 45 to 97.95 wt.% water.

Yet another aspect of the invention relates to an aqueous liquid composition containing: 20-200 g/l digestible dissolved carbohydrates; 0.01 to 10 mM of peptides with ACE inhibiting activity, said peptides exhibiting an IC-50 concentration of less than 1000  $\mu$ M.; and 45 to 97.95 wt.% water.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**